Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Takahiro Akahori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1292-174X; OpenAlex author ID A5110697318. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
109
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 9 papers · 2016: 6 papers · 2017: none · 2018: 2 papers · 2019: 5 papers · 2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 36

  1. Adaptive Surgical Decision-Making for Synchronous Metastatic Pancreatic Cancer and Early Breast Cancer with a BRCA1 Pathogenic Variant: A Case Report. Co-author DOI 10.70352/scrj.cr.26-0257↗
  2. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  3. Total neoadjuvant therapy improves survival of patients with borderline resectable pancreatic cancer with arterial involvement. Co-author DOI 10.1002/ags3.12726↗
  4. Efficacy and safety of neoadjuvant nab-paclitaxel plus gemcitabine therapy in patients with borderline resectable pancreatic cancer: A multicenter single-arm p… Co-author DOI 10.1002/ags3.12712↗
  5. Transcriptomic Profiling Identifies an Exosomal microRNA Signature for Predicting Recurrence Following Surgery in Patients With Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1097/sla.0000000000004993↗
  6. A gene expression signature for predicting response to neoadjuvant chemoradiotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33284↗
  7. Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential. Co-author DOI 10.1016/j.pan.2021.01.013↗
  8. Does direct invasion of peripancreatic lymph nodes impact survival in patients with pancreatic ductal adenocarcinoma? A retrospective dual-center study. Co-author DOI 10.1016/j.pan.2021.03.008↗
  9. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? Co-author DOI 10.3390/jcm10040873↗
  10. Application of liquid biopsy for surgical management of pancreatic cancer. Co-author DOI 10.1002/ags3.12317↗
  11. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases. Co-author DOI 10.1053/j.gastro.2020.04.057↗
  12. Risk Factors for Late-Onset Gastrointestinal Hemorrhage After Pancreatoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s00268-018-4791-7↗
  13. A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Ca… Co-author DOI 10.1007/s00268-018-4820-6↗
  14. Significance of the inflammation-based prognostic score in recurrent pancreatic cancer. Co-author DOI 10.1016/j.pan.2019.05.461↗
  15. A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combi… Co-author DOI 10.1186/s13063-019-3332-5↗
  16. Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2018-0900↗
  17. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00423-018-1709-7↗
  18. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  19. Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreati… Co-author DOI 10.1002/jhbp.318↗
  20. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  21. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic … Co-author DOI 10.1007/s00280-015-2928-z↗
  22. Increased tumour ADC value during chemotherapy predicts improved survival in unresectable pancreatic cancer. Co-author DOI 10.1007/s00330-015-3999-2↗
  23. Factors associated with failure to complete adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2015.10.034↗
  24. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  25. Importance of resectability status in neoadjuvant treatment for pancreatic cancer. First author DOI 10.1002/jhbp.258↗
  26. Prognostic Significance of Muscle Attenuation in Pancreatic Cancer Patients Treated with Neoadjuvant Chemoradiotherapy. Co-author DOI 10.1007/s00268-015-3205-3↗
  27. Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer. First author DOI 10.1007/s00423-015-1304-0↗
  28. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  29. Potential role of surgical resection for pancreatic cancer in the very elderly. Co-author DOI 10.1016/j.pan.2015.03.015↗
  30. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… Co-author DOI 10.1016/j.pan.2015.09.008↗
  31. Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy. Co-author DOI 10.1097/mpa.0000000000000395↗
  32. Nectin-4 expression contributes to tumor proliferation, angiogenesis and patient prognosis in human pancreatic cancer. Co-author DOI 10.1186/s13046-015-0144-7↗
  33. Clinical significance of CD155 expression in human pancreatic cancer. Co-author PMID 25862891↗
  34. Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer. First author DOI 10.1007/s00534-012-0532-8↗
  35. [Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report]. Co-author PMID 23267918↗
  36. Novel postoperative adjuvant strategy prevents early hepatic recurrence after resection of pancreatic cancer. Co-author DOI 10.1007/s00534-010-0336-7↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masayuki Sho · 33 shared papers, 2011–2026 · strength 2.74
  2. Minako Nagai · 22 shared papers, 2015–2024 · strength 1.71
  3. Kota Nakamura · 12 shared papers, 2018–2024 · strength 1.41
  4. Satoshi Nishiwada · 19 shared papers, 2015–2022 · strength 1.35
  5. Kenji Nakagawa · 10 shared papers, 2018–2021 · strength 1.07
  6. Sohei Satoi · 13 shared papers, 2015–2025 · strength 0.94
  7. Naoya Ikeda · 10 shared papers, 2015–2021 · strength 0.81
  8. Yoshiyuki Nakajima · 16 shared papers, 2011–2016 · strength 0.72
  9. Kimihiko Kichikawa · 12 shared papers, 2011–2019 · strength 0.70
  10. Shoichi Kinoshita · 15 shared papers, 2012–2016 · strength 0.67
  11. Tomohisa Yamamoto · 8 shared papers, 2015–2025 · strength 0.61
  12. Hiroki Yamaue · 8 shared papers, 2015–2025 · strength 0.60
  13. Tadataka Takagi · 5 shared papers, 2019–2021 · strength 0.59
  14. Toshihiro Tanaka · 9 shared papers, 2011–2019 · strength 0.54
  15. Hideyuki Nishiofuku · 8 shared papers, 2011–2019 · strength 0.45
  16. Taichi Terai · 3 shared papers, 2021–2024 · strength 0.45
  17. Hiroaki Yanagimoto · 8 shared papers, 2015–2019 · strength 0.42
  18. Satoshi Yasuda · 6 shared papers, 2012–2024 · strength 0.41
  19. Michiaki Unno · 6 shared papers, 2015–2025 · strength 0.39
  20. Ippei Matsumoto · 6 shared papers, 2015–2023 · strength 0.37
  21. Ajay Goel · 3 shared papers, 2020–2022 · strength 0.36
  22. Chiho Ohbayashi · 6 shared papers, 2015–2019 · strength 0.36
  23. Tsutomu Fujii · 3 shared papers, 2019–2025 · strength 0.35
  24. So Yamaki · 5 shared papers, 2015–2021 · strength 0.34
  25. Masaji Tani · 3 shared papers, 2015–2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.